Lifesci Capital Stock Recommendations and Price Targets

This is a list of recent ratings by Lifesci Capital.

DateCompany NameActionCurrent
Price
Price
Target
RatingImpact on
Share Price
6/11/2024
DNTH
Dianthus Therapeutics
Upgrade$26.00Strong-BuyLow
5/28/2024
CALT
Calliditas Therapeutics AB (publ)
Downgrade$39.00Strong-Buy ➝ HoldLow
5/6/2024
CATX
Perspective Therapeutics
Reiterated Rating$10.00OutperformN/A
3/26/2024
MLYS
Mineralys Therapeutics
Reiterated Rating$12.00OutperformLow
2/28/2024
VTYX
Ventyx Biosciences
Upgrade$3.00Market Perform ➝ OutperformLow
2/27/2024
GPCR
Structure Therapeutics
Reiterated Rating$46.00OutperformLow
2/20/2024
LRMR
Larimar Therapeutics
Reiterated Rating$8.00OutperformLow
1/23/2024
INBX
Inhibrx
Downgrade$15.00Outperform ➝ Market PerformLow
1/5/2024
IVA
Inventiva
Reiterated Rating$3.00OutperformLow
12/26/2023
TARS
Tarsus Pharmaceuticals
Reiterated Rating$26.00OutperformLow
12/26/2023
RCKT
Rocket Pharmaceuticals
Reiterated Rating$22.00OutperformLow
12/4/2023
SYRE
Spyre Therapeutics
Reiterated Rating$24.00OutperformLow
11/27/2023
TCRX
TScan Therapeutics
Reiterated Rating$6.00OutperformLow
11/7/2023
VTYX
Ventyx Biosciences
Downgrade$3.00Outperform ➝ Market PerformLow
8/8/2023
TNYA
Tenaya Therapeutics
Reiterated Rating$3.00OutperformLow
8/8/2023
INBX
Inhibrx
Reiterated Rating$15.00OutperformLow
8/8/2023
VERV
Verve Therapeutics
Reiterated Rating$5.00OutperformLow
4/26/2023
PYXS
Pyxis Oncology
Reiterated Rating$3.00OutperformLow
4/26/2023
OLMA
Olema Pharmaceuticals
Reiterated Rating$12.00OutperformLow
4/26/2023
ALXO
ALX Oncology
Reiterated Rating$7.00OutperformLow
4/26/2023
AVDL
Avadel Pharmaceuticals
Reiterated Rating$15.00OutperformLow
4/26/2023
INBX
Inhibrx
Reiterated Rating$15.00OutperformLow
4/24/2023
IRON
Disc Medicine
Reiterated Rating$44.00OutperformLow
4/18/2023
BLU
BELLUS Health
DowngradeC$19.00Outperform ➝ Market PerformN/A
4/11/2023
AKRO
Akero Therapeutics
Reiterated Rating$23.00OutperformLow
4/5/2023
IFRX
InflaRx
Upgrade$2.00Market Perform ➝ OutperformLow
3/31/2023
BTTX
Better Therapeutics
Downgrade$0.00Outperform ➝ Market PerformLow
3/27/2023
CRNX
Crinetics Pharmaceuticals
Reiterated Rating$46.00OutperformLow
3/8/2023
OBIO
Orchestra BioMed
Reiterated Rating$6.00OutperformLow
3/7/2023
ELVN
Enliven Therapeutics
Reiterated Rating$21.00OutperformLow
12/21/2022
MLTX
MoonLake Immunotherapeutics
Reiterated Rating$38.00OutperformN/A
12/1/2022
PYXS
Pyxis Oncology
Reiterated Rating$3.00OutperformLow
11/28/2022
ATXS
Astria Therapeutics
Reiterated Rating$9.00OutperformLow
11/8/2022
ALXO
ALX Oncology
Reiterated Rating$7.00OutperformLow
9/6/2022
AKLI
Akili
Reiterated Rating$0.00OutperformLow
8/12/2022
VYNE
VYNE Therapeutics
Downgrade$2.00Outperform ➝ Market PerformLow
8/12/2022
LRMR
Larimar Therapeutics
Upgrade$8.00Market Perform ➝ OutperformLow
6/16/2022
TNYA
Tenaya Therapeutics
Reiterated Rating$3.00OutperformLow
3/28/2022
VERA
Vera Therapeutics
Reiterated Rating$36.00OutperformLow
3/25/2022
ELDN
Eledon Pharmaceuticals
Reiterated Rating$3.00OutperformMedium
3/22/2022
LHDXQ
Lucira Health
Upgrade$0.00Market Perform ➝ OutperformLow
2/16/2022
LRMR
Larimar Therapeutics
Downgrade$8.00 $3.00Outperform ➝ Market PerformMedium
12/27/2021
BTTX
Better Therapeutics
Reiterated Rating$0.00OutperformHigh
12/22/2021
ALLK
Allakos
Downgrade$1.00Outperform ➝ Market PerformHigh
12/22/2021
VERV
Verve Therapeutics
Reiterated Rating$5.00OutperformHigh
11/17/2021
NNOX
Nano-X Imaging
Downgrade$7.00Outperform ➝ Market PerformLow
11/15/2021
VTYX
Ventyx Biosciences
Reiterated Rating$3.00OutperformHigh
11/4/2021
ALXO
ALX Oncology
Reiterated Rating$7.00OutperformMedium
11/2/2021
PYXS
Pyxis Oncology
Reiterated Rating$3.00OutperformLow
10/24/2021
RCKT
Rocket Pharmaceuticals
Reiterated Rating$22.00OutperformLow
8/26/2021
DRIO
DarioHealth
Reiterated Rating$1.00OutperformHigh
8/24/2021
VRDN
Viridian Therapeutics
Reiterated Rating$13.00OutperformLow
8/13/2021
LHDXQ
Lucira Health
Downgrade$0.00Outperform ➝ Market PerformMedium
8/4/2021
LRMR
Larimar Therapeutics
Reiterated Rating$8.00OutperformMedium